Latest research on Actemra

Tocilizumab is a recombinant, humanized, anti-human interleukin 6 (IL-6) receptor monoclonal antibody that achieves a significant therapeutic response rate. The light chain is made up of 214 amino acids. The heavy chain is made up of 448 amino acids. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. FDA approved on January 8, 2010.

Latest findings

Biologic agents were mainly in decreasing order of frequency: etanercept (Enbrel), adalimumab (Humira), abatacept (Orencia), rituximab (MabThera), and tocilizumab (Actemra). [source, 2016]
Preclinical therapeutic trials were generated using xenografts from tumorigenic MCF7 clones administered with Tamoxifen citrate implants, fulvestrant (Faslodex) and tocilizumab (Actemra). [source, 2016]
Tocilizumab (Actemra, Roche Pharmaceuticals) was diluted in PBS at a final concentration of 20 mg ml−1. [source, 2016]
She suffered from a high level of the interleukin 6 protein, and her doctors suggested trying tocilizumab (Actemra), a rheumatoid arthritis drug, to combat the extraneous protein production [97, 98]. [source, 2016]
The Safety, Tolerability, and Efficacy of Actemra (Tocilizumab) in Rheumatoid Arthritis (STEARA) study (ClinicalTrials.gov NCT01089023) was an open-label, single-arm, phase 4 study conducted at 7 sites throughout 5 countries (Bahrain, Iran, Kuwait, Qatar, and UAE) between January 13, 2010, and June 20, 2011. [source, 2015]
In summary, monotherapy of TCZ (AMBITION, the Actemra versus methotrexate double-blind investigative trial in monotherapy)22 or in combination with MTX is superior to MTX alone or placebo in disease activity remission in duration of at least 24 weeks with Chinese patients’ participation. [source, 2015]
In the RADIATE (research on Actemra determining efficacy after anti-TNF failures) trial, 489 patients with refractory RA with futile treatment with at least one anti-TNF and mean disease duration of 11.0–12.6 years received TCZ (4 mg/kg or 8 mg/kg iv q4w) plus MTX or placebo plus MTX for 24 weeks. [source, 2015]
In the CIA study, clinical-grade TCZ (RoActemra®, 20 mg/mL; Roche, Basel, Switzerland) was administered to the rhesus monkeys undiluted at 0.5 mL/kg (10 mg/kg) as an intravenous bolus injection at indicated doses. [source, 2015]
This mode of action has been clinically validated by the development of TCZ, a monoclonal antibody against IL-6R, marketed as RoActemra® in Europe and Actemra® in the US and elsewhere. [source, 2015]
Tocilizumab, Sarilumab, Atlizumab (Actemra) and Sirukumab are therapeutic monoclonal anti-IL-6R antibodies. [source, 2015]